natgillin/translations-raw huggingface dataset:
I uge 24 var antallet af ASAS 20 responders 15/78 (19 %) i placebogruppen og 123/201 (61 %) i gruppen, der fik 5 mg/kg infliximab (p < 0,001).
At week 24, the number of ASAS 20 responders was 15/78 (19%) in the placebo group, and 123/201 (61%) in the 5 mg/kg infliximab group (p < 0.001).
Tuberkulose, bakterieinfektioner, inklusive sepsis og pneumoni, invasive svampeinfektioner, virale infektioner og andre opportunistiske infektioner er set hos patienter behandlet med infliximab.
Tuberculosis, bacterial infections, including sepsis and pneumonia, invasive fungal, viral, and other opportunistic infections have been observed in patients treated with infliximab.
Efter markedsføring er der rapporteret tilfælde af forværret hjerteinsufficiens hos Remicade patienter, med eller uden identificerbare predisponerende faktorer.
There have been post-marketing reports of worsening heart failure, with and without identifiable precipitating factors, in patients taking Remicade.
Ved uge 14 blev 282 patienter bedømt til klinisk respons og randomiseret til at få enten placebo eller 5 mg/kg infliximab hver 8. uge til og med uge 46.
At week 14, 282 patients were assessed for clinical response and randomised to receive either placebo or 5 mg/kg infliximab every 8 weeks through week 46.
Ikke almindelig: Vaginitis.
Uncommon: Vaginitis.
PGA helt væk (0) eller minimale (1) PGA helt væk (0), minimale (1) eller lette (2) Alle negle fri for psoriasis Uge 10
PGA of cleared (0) or minimal (1) PGA of cleared (0), minimal (1), or mild (2) All nails cleared
Remicades sikkerhed og virkning hos børn under 6 år med Crohns sygdom er ikke klarlagt.
The safety and efficacy of Remicade have not been studied in children with Crohn's disease below the age of 6 years.
• Andre hudproblemer såsom erythema multiforme, lichenoide reaktioner (kløende, rødligt-lilla hududslæt og/eller trådlignende gråhvide linjer på slimhinderne), blærer og afskalning af huden eller bylder (furunkulose)
• Other skin problems such as erythema multiforme, lichenoid reactions (itchy reddish-purple skin rash and/or threadlike white-grey lines on mucous membranes), blisters and peeling skin,
Der er rapporteret om melanom og Merkelcellekarcinom hos patienter, der har fået TNF-blokerende behandling, herunder Remicade (se pkt.
Melanoma and Merkel cell carcinoma have been reported in patients treated with TNF blocker therapy, including Remicade (see section 4.8).
Under behandling med Remicade
During treatment with Remicade
≥ 50 % forbedring
≥ 50% improvement
• Manglende blodtilførsel, hævelse af en blodåre
• Shortage of blood supply, swelling of a vein
Med den nuværende viden kan en mulig risiko for udvikling af lymfomer eller andre maligne sygdomme hos patienter behandlet med et TNF-blokerende middel ikke udelukkes (se pkt.
With the current knowledge, a risk for the development of lymphomas or other malignancies in patients treated with a TNF-blocking agent cannot be excluded (see section 4.8).
I det første studie (P01522), som havde en dobbelblind fase på 3 måneder, modtog 70 patienter enten 5 mg/kg infliximab eller placebo i uge 0, 2, 6 (35 patienter i hver gruppe).
In the first study (P01522), which had a 3 month double-blind phase, 70 patients received either 5 mg/kg infliximab or placebo at weeks 0, 2, 6 (35 patients in each group).
Se afsnittet om Graviditet, amning og frugtbarhed for yderligere information.
For more information see section on Pregnancy and breast-feeding.
Infliximabvedligeholdelse 5 mg/kg (n = 113) (p-værdi)
Infliximab Maintenance 5 mg/kg (n = 113) (p value)
I kliniske studier er infektioner rapporteret hyppigere hos pædiatriske patienter end hos voksne patienter (se pkt.
In clinical studies, infections have been reported in a higher proportion of paediatric patients compared to adult patients (see section 4.8).
I uge 12 blev placebopatienter skiftet over til infliximab 5 mg/kg hver 6. uge indtil uge 54.
At week 12, placebo patients were switched to infliximab 5 mg/kg every 6 weeks up to week 54.
Median opfølgningsperioden var 0,8 år (incidens 5,7 % [95 % CI 2,65 %-10,6 %].
5.7% [95% CI 2.65%-10.6%].
Moderat til svært aktiv Crohns sygdom
Moderately to severely active Crohn's disease
Patientinformationskort
Patient Reminder Card
Tegn og symptomer inkluderede myalgi og/eller artralgi med feber og/eller udslæt, og nogle patienter oplevede kløe, ansigts-, hånd eller læbeødem, dysfagi, urticaria, ondt i halsen og hovedpine.
Signs and symptoms included myalgia and/or arthralgia with fever and/or rash, with some patients experiencing pruritus, facial, hand or lip oedema, dysphagia, urticaria, sore throat and headache.
I alt 306 patienter fik 3 doser infliximab på 5 mg/kg i ugerne 0, 2 og 6.
A total of 306 patients received 3 doses of infliximab 5 mg/kg at week 0, 2 and 6.
Infliximabvedligeholdelse 10 mg/kg (n = 112) (p-værdi)
Infliximab Maintenance 10 mg/kg (n = 112) (p value)
• Hudproblemer såsom blæredannelse, vorter, unormal hudfarve eller pigmentering, eller hævede læber, eller fortykkelse af huden eller rød, skællende hud og afskalning af huden
• Skin problems such as blistering, warts, abnormal skin colouration or pigmentation, or swollen lips, or thickening of the skin, or red, scaly, and flaky skin
Der er rapporteret om enkelte tilfælde af aktiv tuberkulose under og efter behandling for latent tuberkulose hos patienter i behandling med Remicade.
Some cases of active tuberculosis have been reported in patients treated with Remicade during and after treatment for latent tuberculosis.
Remicade er indiceret til behandling af moderat til svær, aktiv colitis ulcerosa hos voksne patienter, som har haft utilstrækkelig respons af konventionel behandling inklusive kortikosteroider og 6
Remicade is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and
Almindelig: Unormal leverfunktion, forhøjede leveraminotransferaser.
Common: Hepatic function abnormal, transaminases increased.
De mest almindeligt rapporterede infektioner var øvre luftvejsinfektioner og pharyngitis.
The most commonly reported infections were upper respiratory tract infection and pharyngitis, and the most commonly reported serious infection was abscess.
De patienter, som af investigator blev vurderet til at have et klinisk respons i uge 10, blev randomiseret og fik 5 mg/kg infliximab enten hver 8. eller hver 12. uge som et vedligeholdelsesbehandlingsregime.
Patients assessed by the investigator to be in clinical response at week 10 were randomised and received 5 mg/kg infliximab at either q8 weeks or q12 weeks as a maintenance treatment regimen.
Hvis du har aktiv reumatoid arthritis, vil du først få andre lægemidler.
If you have active rheumatoid arthritis you will first be given other medicines.
Seponering af Remicadebehandling bør overvejes hos patienter, hvor signifikante blodanormaliteter er bekræftet.
Discontinuation of Remicade therapy should be considered in patients with confirmed significant haematologic abnormalities.
5.1): anæmi (10,7 %), blod i afføringen (9,7 %), leukopeni (8,7 %), rødmen (8,7 %), viral infektion (7,8 %), neutropeni (6,8 %), bakteriel infektion (5,8 %) og allergisk reaktion i luftvejene (5,8 %).
The following adverse reactions were reported more commonly in paediatric Crohn's disease patients in the REACH study (see section 5.1) than in adult Crohn's disease patients: anaemia (10.7%), blood in stool (9.7%), leucopenia (8.7%), flushing (8.7%), viral infection (7.8%), neutropenia (6.8%), bacterial infection (5.8%), and respiratory tract allergic reaction (5.8%).
• Bivirkninger i forbindelse med infusionen
• Side effect due to an infusion
Total score d (van der Heijdemodified Sharp score) Ændring fra baseline (Gennemsnit  SD
Heijde-modified Sharp score) Change from baseline (Mean ± SD
Andelen af patienter med slimhindeheling i uge 26 var signifikant større i grupperne, der fik infliximab plus AZA (43,9 %; p < 0,001) eller infliximab-monoterapi (30,1 %; p = 0,023) sammenlignet med AZA-monoterapigruppen (16,5 %).
The proportions of patients with mucosal healing at week 26 were significantly greater in the infliximab plus AZA combination (43.9%, p < 0.001) and infliximab monotherapy groups (30.1%, p = 0.023) compared to the AZA monotherapy group (16.5%).
Patienterne modtog tre doser af enten placebo eller infliximab i uge 0, 2 og 6.
Patients received three doses of either placebo or infliximab at weeks 0, 2 and 6.
• Øvrige indholdsstoffer: saccharose, polysorbat 80, natriumdihydrogenphosphat og dinatriumphosphatdihydrat.
• The other ingredients are sucrose, polysorbate 80, monobasic sodium phosphate and dibasic sodium phosphate.
Remicade er indiceret til behandling af svær, aktiv colitis ulcerosa hos børn og unge i alderen 6 til 17 år, som har responderet utilstrækkeligt på konventionel behandling, inklusive kortikosteroider og 6-MP eller AZA, eller som er intolerante over for eller hvor der er kontraindikationer mod disse behandlinger.
Remicade is indicated for treatment of severely active ulcerative colitis, in children and adolescents aged 6 to 17 years, who have had an inadequate response to conventional therapy including corticosteroids and 6-MP or AZA, or who are intolerant to or have medical contraindications for such therapies.
Tegn inkluderer feber, hoste, influenzalignende symptomer, utilpashed, rød eller ophedet hud, sår eller problemer med tænderne.
Signs include fever, cough, flu-like signs, feeling unwell, red or hot skin, wounds or dental problems.
Spontane alvorlige bivirkninger hos børn efter markedsføring af infliximab inkluderer malignititer inklusive hepatosplenisk T-celle-lymfom, forbigående leverenzymabnormaliteter, lupus lignende syndromer og positive autoantistoffer (se pkt.
Post-marketing spontaneous serious adverse reactions with infliximab in the paediatric population have included malignancies including hepatosplenic T-cell lymphomas, transient hepatic enzyme abnormalities, lupus-like syndromes, and positive auto-antibodies (see sections 4.4 and 4.8).
Du må ikke få Remicade og Orencia samtidig.
Remicade and Orencia should not be used together.
• Blødning i mave eller tarme, diarré, fordøjelsesbesvær, halsbrand, forstoppelse
• Bleeding in the stomach or intestines, diarrhoea, indigestion, heartburn, constipation
Ikke almindelig: Trombocytopeni, lymfopeni, lymfocytose.
Uncommon: Thrombocytopenia, lymphopenia, lymphocytosis.
Almindelig: Gastrointestinal blødning, diarré, dyspepsi, gastroøsofageal refluks, forstoppelse.
Common: Gastrointestinal haemorrhage, diarrhoea, dyspepsia, gastroesophageal reflux, constipation.
Den almindeligste bivirkning rapporteret i kliniske studier var øvre luftvejsinfektion, der forekom hos 25,3 % af de infliximab-behandlede patienter sammenlignet med hos 16,5 % af kontrolpatienterne.
Upper respiratory tract infection was the most common adverse drug reaction (ADR) reported in clinical trials, occurring in 25.3% of infliximab-treated patients compared with 16.5% of control patients.
• Trætheds- eller svaghedsfølelse
• Feeling tired or weak
Remicade er indiceret til behandling af svær, aktiv Crohns sygdom hos børn og unge mellem 6 og 17 år, som ikke har responderet på konventionel behandling inklusive kortikosteroid, immunmodulator og primær ernæringsbehandling, eller som er intolerante over for eller hvor der er kontraindikationer mod sådanne behandlinger.
Remicade is indicated for treatment of severe, active Crohn's disease, in children and adolescents aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy; or who are intolerant to or have contraindications for such therapies.
Ikke almindelig: Bulløst udslæt, seborre, rosacea, hudpapilom, hyperkeratose, unormal hudpigmentering.
Uncommon: Bullous eruption, seborrhoea, rosacea, skin papilloma, hyperkeratosis, abnormal skin pigmentation.
Været i behandling med Remicade tidligere
Had treatment with Remicade before
Antallet af hospitalsindlæggelser relateret til colitis ulcerosa var signifikant lavere i 5 og 10 mg/kg infliximab-behandlingsgrupperne end i placebogruppen (gennemsnitligt antal hospitalsindlæggelser per 100 forsøgsperson-år: 21 og 19 versus 40 i placebogruppen; hhv. p = 0,019 og p = 0,007).
The number of ulcerative colitis-related hospitalisations was significantly lower in the 5 and 10 mg/kg infliximab treatment groups than in the placebo group (mean number of hospitalisations per 100 subject-years: 21 and 19 vs. 40 in the placebo group; p = 0.019 and p = 0.007, respectively).
• Lungehindebetændelse, der giver skape smerter, som forværres ved vejrtrækning (pleuritis)
• Inflamed lining of the lung, causing sharp chest pains that feel worse with breathing (pleurisy)
Hos patienter, som fik Remicade, er langt de fleste tilfælde forekommet hos patienter med Crohns sygdom eller colitis ulcerosa og de fleste blev rapporteret hos unge eller unge voksne mænd.
The vast majority of Remicade cases have occurred in patients with Crohn's disease or ulcerative colitis and most were reported in adolescent or young adult males.
Klinisk respons i uge 30
Clinical response at week 30
Fortsat behandling bør revurderes nøje hos patienter, som ikke viser tegn på terapeutisk effekt inden for denne periode.
Continued therapy should be carefully reconsidered in patients who show no evidence of therapeutic benefit within this time period.
• Alvorlige allergiske reaktioner (fx anafylaksi), en sygdom i immunsystemet kaldet lupus,
• Severe allergic reactions (e.g. anaphylaxis), an immune system disorder called lupus, allergic reactions to foreign proteins
Der blev observeret alvorlige infektioner og neutropeni i kliniske studier ved samtidig anvendelse af anakinra og et andet TNFα-blokerende middel, etanercept, uden nogen øget klinisk fordel sammenlignet med etanercept indgivet alene.
Concurrent administration of TNF-alpha inhibitor and anakinra Serious infections and neutropenia were seen in clinical studies with concurrent use of anakinra and another TNF-blocking agent, etanercept, with no added clinical benefit compared to etanercept alone.
PGA helt væk (0), minimale (1) eller lette (2)
PGA of cleared (0), minimal (1), or mild (2)
Hud og subkutane væv Almindelig: Debuterende eller forværring af allerede eksisterende psoriasis, inklusive pustuløs psoriasis (primært palmoplantaris), urticaria, udslæt, pruritus, øget svedtendens, tør hud, svampedermatitis, eksem, alopeci.
Common: New onset or worsening psoriasis including pustular psoriasis (primarily palm & soles), urticaria, rash, pruritus, hyperhidrosis, dry skin, fungal dermatitis, eczema, alopecia.
Ikke almindelig: Lungeødem, bronkospasme, pleuritis, pleural effusion.
Uncommon: Pulmonary oedema, bronchospasm, pleurisy, pleural effusion.
• Tegn på en sygdom i immunsystemet såsom ledsmerter, udslæt på kinder eller arme, som er følsomme over for solen (lupus) eller hoste, åndenød, feber eller hududslæt (sarkoidose).
• Signs of an immune system disorder such as joint pain or a rash on cheeks or arms that is sensitive to the sun (lupus) or cough, shortness of breath, fever or skin rash (sarcoidosis).
Ikke kendt: Kortvarigt synstab under infusionen eller inden for 2 timer efter infusionen.
Not known: Transient visual loss occurring during or within 2 hours of infusion.
Der er set pancytopeni, leukopeni, neutropeni og trombocytopeni hos patienter, der fik TNFhæmmere, herunder Remicade.
There have been reports of pancytopenia, leucopenia, neutropenia, and thrombocytopenia in patients receiving TNF-blockers, including Remicade.
Samtidig anvendelse af TNF-alfahæmmere og abatacept har i kliniske studier været forbundet med en øget risiko for infektioner, inklusive alvorlige infektioner, uden en øget klinisk fordel, sammenlignet med TNF-hæmmere alene.
Concurrent administration of TNF-alpha inhibitor and abatacept In clinical studies concurrent administration of TNF-antagonists and abatacept has been associated with an increased risk of infections including serious infections compared to TNF-antagonists alone, without increased clinical benefit.
Antallet af kirurgiske indgreb relateret til colitis ulcerosa var også lavere i 5 og 10 mg/kg infliximab-behandlingsgrupperne end i placebogruppen (gennemsnitligt antal kirurgiske indgreb per 100 forsøgsperson-år: 22 og 19 versus 34; hhv. p = 0,145 og p = 0,022).
The number of ulcerative colitis-related surgical procedures was also lower in the 5 and 10 mg/kg infliximab treatment groups than in the placebo group (mean number of surgical procedures per 100 subject-years: 22 and 19 vs. 34; p = 0.145 and p = 0.022, respectively).
Fortæl straks din læge, hvis du får nye eller forværrede tegn på hjertesvigt under behandlingen med Remicade.
Tell your doctor straight away if you get new or worsening signs of heart failure during treatment with Remicade.
I et populationsbaseret, retrospektivt kohortestudie sås en øget incidens af livmoderhalskræft hos kvinder med reumatoid artrit, som var blevet behandlet med infliximab, sammenlignet med patienter, der var naive i forhold til biologiske lægemidler, eller befolkningen generelt, inklusive kvinder over 60 år (se pkt.
A population-based retrospective cohort study found an increased incidence of cervical cancer in women with rheumatoid arthritis treated with infliximab compared to biologics-naïve patients or the general population, including those over 60 years of age (see section 4.4).
p < 0,001, for hver infliximab-behandlingsgruppe mod kontrol.
p < 0.001, for each infliximab treatment group vs. control.
Sjælden: Kredsløbssvigt, petekkier, vasospasme.
Rare: Circulatory failure, petechia, vasospasm.
I uge 4 efter indgivelse af en enkelt dosis opnåede 22/27 (81 %) af de infliximab-behandlede patienter, der fik 5 mg/kg dosen en klinisk effekt mod 4/25 (16 %) af placebopatienterne (p < 0,001).
At week 4, following administration of a single dose, 22/27 (81%) of infliximab-treated patients receiving a 5 mg/kg dose achieved a clinical response vs. 4/25 (16%) of the placebo-treated patients (p < 0.001).
Klinisk remission og slimhindeheling forekom i en større andel af patienterne i den kombinerede infliximab behandlingsgruppe sammenlignet med placebobehandlingsgruppen i uge 54 (henholdsvis 34,6 % mod16,5 %, p < 0,001 og 46,1 % mod 18,2 %, p < 0,001).
Clinical remission and mucosal healing occurred in a greater proportion of patients in the combined infliximab treatment group compared to the placebo treatment group at week 54 (34.6% vs. 16.5%, p < 0.001 and 46.1% vs. 18.2%, p < 0.001, respectively).
Fornyet indgift ved psoriasis
Re-administration for psoriasis
Fistulerende, aktiv Crohns sygdom
Fistulising, active Crohn's disease
Andelene af patienter i vedvarende respons og vedvarende remission i uge 54 var større i den kombinerede infliximab-behandlingsgruppe end i placebobehandlingsgruppen (henholdsvis 37,9 % mod 14,0 %, p < 0,001 og 20,2 % mod 6,6 %, p < 0,001).
The proportions of patients in sustained response and sustained remission at week 54 were greater in the combined infliximab treatment group than in the placebo treatment group (37.9% vs. 14.0%, p < 0.001; and 20.2% vs. 6.6%, p < 0.001, respectively).
Nødudstyr såsom adrenalin, antihistaminer, kortikosteroider, tungeholder og Rubens ballon skal være tilgængeligt.
Emergency equipment, such as adrenaline, antihistamines, corticosteroids and an artificial airway must be available.
Det anbefales, at pædiatriske patienter bliver vaccineret i overensstemmelse med gældende vaccinationsvejledninger, før Remicadebehandling påbegyndes, hvis dette er muligt.
It is recommended that paediatric patients, if possible, be brought up to date with all vaccinations in agreement with current vaccination guidelines prior to initiating Remicade therapy.
Almindelig: Brystsmerte, træthed, feber, reaktioner på injektionsstedet, kulderystelser, ødem.
Common: Chest pain, fatigue, fever, injection site reaction, chills, oedema.
Remicade 100 mg pulver til koncentrat infliximab i.v.
Remicade 100 mg powder for concentrate infliximab
• Tegn på infektion (inklusive tuberkulose (TB)) såsom feber, træthedsfølelse, hoste, der kan være vedvarende, åndenød, influenzalignende symptomer, vægttab, natlig svedtendens, diarré, sår, ansamling af pus i tarmen eller omkring anus (absces), tandproblemer eller brændende smerte, når du lader vandet.
• Signs of infection (including TB) such as fever, feeling tired, cough which may be persistent, shortness of breath, flu-like symptoms, weight loss, night sweats, diarrhoea, wounds, collection of pus in the gut or around the anus (abscess), dental problems or burning sensation when urinating.
Efter markedsføring har tilfælde af hepatosplenisk T-celle-lymfom (HSTCL) været rapporteret hos patienter behandlet med TNF-blokkere inklusive infliximab.
Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with TNF-blocking agents including infliximab.
Der er set tilfælde af aktiv tuberkulose hos patienter behandlet med Remicade.
There have been reports of active tuberculosis in patients receiving Remicade.
Natriumdihydrogenphosphat Dinatriumphosphatdihydrat
Monobasic sodium phosphate Dibasic sodium phosphate
Almindelig: Allergiske luftvejssymptomer.
Immune system disorders Common: Allergic respiratory symptom.
Patienterne fik placebo, 3 mg/kg eller 10 mg/kg infliximab i ugerne 0, 2 og 6, samt hver 4. eller 8. uge herefter.
Patients received placebo, 3 mg/kg or 10 mg/kg infliximab at weeks 0, 2 and 6, and then every 4 or 8 weeks thereafter.
Det frarådes også at give levende vacciner til spædbørn, der har været eksponeret for infliximab i uterus, i mindst 6 måneder efter fødslen (se pkt.
It is also recommended that live vaccines not be given to infants after in utero exposure to infliximab for at least 6 months following birth (see section 4.4).
• Tegn på lave blodtal såsom vedvarende feber, blødningstendens, tendens til lettere at få blå mærker, små røde eller lilla pletter, der skyldes blødning under huden, eller bleghed.
• Signs of low blood counts such as persistent fever, bleeding or bruising more easily, small red or purple spots caused by bleeding under the skin, or looking pale.
Hos psoriasis patienter behandlet med infliximab som vedligeholdelsesbehandling uden samtidige immunmodulerende midler udviklede 28 % antistoffer mod infliximab (se pkt.
In psoriasis patients treated with infliximab as a maintenance regimen in the absence of concomitant immunomodulators, approximately 28% developed antibodies to infliximab (see section 4.4: “Infusion reactions and hypersensitivity”).
Nogle tilfælde har resulteret i et dødsfald.
Some of the cases have resulted in a fatal outcome.
Efter infliximabbehandling udviste patienter nedsat niveau af serum interleukin 6 (IL-6) og C-reaktiv protein (CRP).
After infliximab treatment, patients exhibited decreased levels of serum interleukin 6 (IL-6) and C-reactive protein (CRP), and increased haemoglobin levels in rheumatoid arthritis patients with reduced haemoglobin levels, compared with baseline.
• Blodproblemer såsom blodmangel eller lavt antal hvide blodlegemer
• Blood problems such as anaemia or low white blood cell count
• Vedligeholdelsesbehandling: Yderligere infusionsdosis på 5 mg/kg 6 uger efter den første dosis, efterfulgt af infusionsdoser hver 8. uge eller
• Maintenance: Additional infusion of 5 mg/kg at 6 weeks after the initial dose, followed by infusions every 8 weeks or
Hvis en patient ikke viser respons efter 14 uger (det vil sige efter 4 doser), bør der ikke gives yderligere behandling med infliximab.
If a patient shows no response after 14 weeks (i.e. after 4 doses), no additional treatment with infliximab should be given.
Tegn omfatter vedvarende feber, større tendens til blødning eller blå mærker, små røde eller lilla pletter, der skyldes blødning under huden, eller bleghed.
Signs include persistent fever, bleeding or bruising more easily, small red or purple spots caused by bleeding under the skin, or looking pale.
Tegn inkluderer vedvarende hoste, vægttab, træthedsfølelse, feber eller natlig svedtendens.
Signs include persistent cough, weight loss, feeling tired, fever, night sweats.